SỰ THAY ĐỔI NỒNG ĐỘ HBsAg Ở NGƯỜI BỆNH VIÊM GAN VI RÚT B MẠN ĐIỀU TRỊ THUỐC KHÁNG VI RÚT TẠI VIỆN Y HỌC NHIỆT ĐỚI BẠCH MAI

Abstract

Objective: To examine changes in hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B receiving antiviral therapy at the Bach Mai Institute of Tropical Medicine, Bach Mai Hospital. Subjects: A total of 190 patients diagnosed with chronic hepatitis B and treated at the Institute of Tropical Medicine, Bach Mai Hospital between August 2010 and August 2025 were selected using convenience sampling. Methods: A retrospective descriptive study. Results and conclusions: The mean HBsAg level decreased rapidly during the first two years of antiviral treatment (mean HBsAg level before treatment: 6311,7 IU/mL; after 6 months: 6724,4 IU/mL; and after 24 months: 3009,3 IU/mL). Thereafter, the mean HBsAg level declined more slowly in subsequent years, reaching 1004,9 IU/mL after 66 months of treatment. The proportion of patients with HBsAg levels ≥10,000 IU/mL decreased markedly during treatment, from 41,1% before treatment to 15,9% after 6 months, 11,2% after 24 months, 4,2% after 36 months, and 0% after 66 months. The rate of HBsAg loss after 30 months of treatment was 1,4% (1/72 patients), increasing to 2,8% after 36 months (2/71 patients), 3,2% after 48 months (2/62 patients), 6,8% after 60 months (4/59 patients), and 9,7% after 66 months of treatment (3/31 patients).